Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
The inclusion of productivity value in the appraisal of health technologies is a subject of ongoing debate. In this blog, we discuss the potential impact of…
Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?
4 August 2020
In a recently published OHE Consulting Report, we report the long-term return on investment (ROI) per £1 spent on various vaccination programmes from the perspective of…
NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?
30 July 2020
OHE publishes a report quantifying the level of patient access associated with NICE ‘optimised’ recommendations.
How Should the World Pay for a COVID-19 Vaccine?
29 April 2020
Prof. Adrian Towse discusses the options for funding the development and manufacture of a vaccine, reflecting on their strengths and weaknesses, considering what may happen with…
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
Research by OHE and the University of Washington into how uncertainty-related novel elements of value could be included in an Augmented Cost-Effectiveness Analysis has been published…
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
This presentation to the Australian Society for Antimicrobials (ASA) meeting in Melbourne, on 27th February 2020 draws on OHE research, funded by the Wellcome Trust, on…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
OHE has published a white paper discussing the relative merits and shortfalls of current approaches to defining, estimating, and applying cost-effectiveness thresholds in HTA. This will…
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
OHE Lunchtime Seminar with Alistair McGuire, 3rd February 2020. The seminar will present some preliminary thoughts on the promises offered by personalised medicine that it will…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
13 January 2020
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting…